EMPA-KIDNEY
Study of Heart and Kidney Protection with Empagliflozin
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.
N
6 609
Schéma
Double-blind RCT, stopped early
Critère
CKD progression or cardiovascular death
Pertinence
2
Résultat13.1% vs 16.9%; HR 0.72 (95% CI 0.64–0.82; p<0.001)
The EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023;388(2):117-127. 10.1056/NEJMoa2204233
Discussion et critique
Widest CKD eligibility yet (eGFR down to 20); no significant benefit in the UACR <30 mg/g subgroup.